Amphastar Pharmaceuticals, Inc. (AMPH)
Amphastar Pharmaceuticals, Inc. (AMPH) is a specialty pharmaceutical company that develops, manufactures, and markets generic and proprietary injectable and infusion drugs. The company serves hospitals, clinics, and other healthcare providers across the United States, focusing on products for critical care, cardiology, neurology, and other therapeutic areas.
What the company does
Amphastar Pharmaceuticals develops and manufactures sterile injectable drugs, primarily serving hospital and acute-care settings. Its product portfolio includes both generic versions of established drugs and proprietary formulations. The company operates a registered manufacturing facility and distributes its products through both direct channels to hospitals and health systems and through pharmaceutical wholesalers. The therapeutic focus spans critical care medications, injectables used in cardiovascular procedures, anesthesia, and neurological treatments.
How it makes money
The company generates revenue primarily from product sales of its injectable formulations. Revenue derives from two main channels: direct sales to large hospital systems and health networks, and wholesale distribution through major pharmaceutical distributors. A portion of revenue also comes from contract manufacturing arrangements where the company manufactures products for other pharmaceutical firms. Margins vary depending on the product mix—proprietary formulations typically command higher margins than generic products, which face more commodity-like pricing pressure from competing manufacturers.
Manufacturing and supply
Amphastar operates or controls manufacturing facilities that produce injectable drug formulations under FDA regulation and cGMP (current good manufacturing practice) standards. Maintaining FDA approval and compliance with manufacturing regulations is critical to the business, as any loss of manufacturing certification or supply disruption can directly impact revenue. The company sources active pharmaceutical ingredients and excipients from suppliers, making supply chain management an ongoing operational focus.
Where it sits in its industry
The specialty injectable pharmaceutical space is competitive and fragmented, with players ranging from large, diversified pharmaceutical giants to smaller, focused manufacturers. Amphastar competes with larger companies that have more resources for R&D and marketing, as well as with other specialty injectable manufacturers on price, product quality, delivery reliability, and hospital relationships. The company’s survival and growth depend on securing and maintaining formulary positions with major hospital networks, which often conduct competitive bidding for generic injectable drugs.
Regulatory and development
As a manufacturer of FDA-approved drugs, Amphastar must comply with stringent manufacturing, quality, and safety regulations. New product development involves obtaining FDA approval via ANDA (Abbreviated New Drug Application) for generic drugs or NDA (New Drug Application) for proprietary formulations. The company faces ongoing patent and regulatory scrutiny and must maintain manufacturing approvals and compliance audits. Changes in healthcare reimbursement rates, hospital consolidation, and shifts in drug purchasing practices can materially affect the business.
How to research it
For current financial information and filings, review Amphastar’s periodic reports with the SEC, including its 10-K annual report and quarterly 10-Q filings. The company’s investor relations site typically provides earnings releases, presentations, and guidance. Industry analysis of the specialty pharmaceuticals and injectable drug market can provide context for competitive positioning. News coverage of hospital purchasing, FDA actions, and pharmaceutical supply chain developments may affect the stock and business outlook.